Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.79Last Year’s EPS
0.75Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -15.75%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance, with strong cash flow, debt repayment, and new product launches being significant positives. However, flat sales, a substantial decline in enabling technology sales, and supply chain disruptions presented notable challenges. The acquisition of Nevro offers future growth opportunities, but the current quarter's results indicate areas needing improvement.Company Guidance
During Globus Medical's Q1 2025 earnings call, the company reported a slight decline in revenue of 0.8% on a constant currency basis, with sales totaling $598 million. Non-GAAP EPS increased by 9% to $0.68, despite a higher diluted share count and the absence of a $0.06 one-time gain from the previous year. Free cash flow reached a record $141 million, marking a 493% increase from the prior year. The company successfully returned to debt-free status by repaying the remaining $900 million debt from the NuVasive merger and announced a $250 million acquisition of Nevro. U.S. Spine revenue grew by 2%, while the enabling technology segment saw a 31% decline to $22 million. Despite Q1 challenges, including supply chain disruptions and elongated sales cycles, Globus Medical remains optimistic about improved performance in Q2 and reaffirmed its annual sales guidance of $2.8 to $2.9 billion, albeit with a slight reduction in EPS guidance to $3.00-$3.30 due to Nevro-related costs.Strong Cash Flow and Debt Repayment
Globus Medical achieved a record free cash flow of $141 million in Q1, increasing 493% versus the prior year. The company returned to debt-free status by paying off nearly $900 million in debt inherited from the NuVasive merger.
New Product Launches
In Q1, Globus Medical launched two new products: the Cohere ALIF spacer and the Reline eGPS fixation system, which are expected to drive market penetration and improve patient outcomes.
U.S. Spine Business Growth
U.S. Spine grew 2% in Q1, driven by high retention rates, strong product offerings, and increased cross-selling and implant pull-through from robotic procedures.
Nevro Acquisition
The company completed the acquisition of Nevro for $250 million, expanding its reach into a $3 billion market space and enhancing its technology portfolio.
---
GMED Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GMED Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $72.46 | $55.82 | -22.96% |
Feb 20, 2025 | $84.12 | $80.28 | -4.56% |
Nov 05, 2024 | $75.58 | $82.71 | +9.43% |
Aug 06, 2024 | $69.05 | $70.53 | +2.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Globus Medical (GMED) report earnings?
Globus Medical (GMED) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Globus Medical (GMED) earnings time?
Globus Medical (GMED) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMED EPS forecast?
GMED EPS forecast for the fiscal quarter 2025 (Q2) is 0.79.
---